Compare IQV & MTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IQV | MTB |
|---|---|---|
| Founded | 1982 | 1856 |
| Country | United States | United States |
| Employees | 93000 | 21866 |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6B | 35.0B |
| IPO Year | 2013 | N/A |
| Metric | IQV | MTB |
|---|---|---|
| Price | $203.92 | $234.72 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 16 | 17 |
| Target Price | $227.13 | ★ $228.59 |
| AVG Volume (30 Days) | ★ 1.5M | 1.0M |
| Earning Date | 05-05-2026 | 04-15-2026 |
| Dividend Yield | N/A | ★ 2.78% |
| EPS Growth | ★ 4.67 | N/A |
| EPS | ★ 1.61 | N/A |
| Revenue | ★ $9,739,000,000.00 | N/A |
| Revenue This Year | $6.77 | $9.87 |
| Revenue Next Year | $5.89 | $3.66 |
| P/E Ratio | $129.54 | ★ $13.63 |
| Revenue Growth | ★ 41.60 | N/A |
| 52 Week Low | $154.50 | $174.76 |
| 52 Week High | $247.05 | $243.57 |
| Indicator | IQV | MTB |
|---|---|---|
| Relative Strength Index (RSI) | 66.57 | 55.85 |
| Support Level | $159.91 | $211.90 |
| Resistance Level | $209.48 | $239.00 |
| Average True Range (ATR) | 7.02 | 4.28 |
| MACD | 2.45 | -0.13 |
| Stochastic Oscillator | 84.77 | 50.77 |
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
M&T Bank is a US regional bank with around $215 billion in assets as of the end of the first quarter of 2026. Headquartered in Buffalo, New York, the bank's footprint is mostly concentrated in New England and the US Mid-Atlantic. M&T Bank boasts a community banking approach, and boasts over 900 branches in 13 states and Washington, D.C. Apart from retail and commercial banking, M&T Bank also has wealth management operations through Wilmington Trust and a partnership with LPL Financial, and a corporate trust business.